Journey Medical Corp — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Claude Maraoui (President/CEO) and Joseph Benesch (CFO) issued standard Sarbanes-Oxley certifications (Section 302 and 906) for the Q2 2026 Form 10-Q period ended June 30, 2026, dated August 12, 2026. Both officers certified that the quarterly report contains no material misstatements, that financial statements fairly present the company's condition and results, and that disclosure controls and internal controls over financial reporting are operating effectively. No specific control deficiencies, material weaknesses, or fraud disclosures were flagged in these exhibits.
Why this rating
Routine SOX certification exhibits; boilerplate legal requirement. No material facts, transactions, or control issues disclosed. Standard periodic disclosure.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.